Summary
High-dose chemotherapy followed by blood stem cell transplantation is administered to
lymphoma patients with an intention to cure. However, high-dose chemotherapy
simultaneously causes damage to healthy tissues that frequently result in severe
complications that lead to hospitalization and can be life threatening. These severe
complications involve the blood, immune, gastro-intestinal systems, and other vital
organs.
The purpose of this study is to determine if experimental therapy AB-205 (study drug) can
prevent or reduce the occurrence and duration of the severe chemotherapy related
complications when compared to placebo in patients with lymphoma undergoing treatment
with high-dose chemotherapy and blood stem cell transplantation. All patients, whether
treated with AB-205 or placebo, will receive standard preventive and supportive care
therapies.